Advertisement

Table of Contents

June 29, 2017; 129 (26)

INSIDE BLOOD COMMENTARIES

BLOOD SPOTLIGHT

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

  • Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
    Wei Ding, Betsy R. LaPlant, Timothy G. Call, Sameer A. Parikh, Jose F. Leis, Rong He, Tait D. Shanafelt, Sutapa Sinha, Jennifer Le-Rademacher, Andrew L. Feldman, Thomas M. Habermann, Thomas E. Witzig, Gregory A. Wiseman, Yi Lin, Erik Asmus, Grzegorz S. Nowakowski, Michael J. Conte, Deborah A. Bowen, Casey N. Aitken, Daniel L. Van Dyke, Patricia T. Greipp, Xin Liu, Xiaosheng Wu, Henan Zhang, Charla R. Secreto, Shulan Tian, Esteban Braggio, Linda E. Wellik, Ivana Micallef, David S. Viswanatha, Huihuang Yan, Asher A. Chanan-Khan, Neil E. Kay, Haidong Dong and Stephen M. Ansell

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

  • Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
    Francesca Gorini, Laura Azzimonti, Gloria Delfanti, Lydia Scarfò, Cristina Scielzo, Maria Teresa Bertilaccio, Pamela Ranghetti, Alessandro Gulino, Claudio Doglioni, Arianna Di Napoli, Miriam Capri, Claudio Franceschi, Federico Caligaris-Cappio, Paolo Ghia, Matteo Bellone, Paolo Dellabona, Giulia Casorati and Claudia de Lalla
  • Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
    Michelle M. McDonald, Michaela R. Reagan, Scott E. Youlten, Sindhu T. Mohanty, Anja Seckinger, Rachael L. Terry, Jessica A. Pettitt, Marija K. Simic, Tegan L. Cheng, Alyson Morse, Lawrence M. T. Le, David Abi-Hanna, Ina Kramer, Carolyne Falank, Heather Fairfield, Irene M. Ghobrial, Paul A. Baldock, David G. Little, Michaela Kneissel, Karin Vanderkerken, J. H. Duncan Bassett, Graham R. Williams, Babatunde O. Oyajobi, Dirk Hose, Tri G. Phan and Peter I. Croucher

MYELOID NEOPLASIA

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

PLATELETS AND THROMBOPOIESIS

LETTERS TO BLOOD

BLOOD WORK